Metabolism, Circadian Rhythms and Ovarian Function
- Conditions
- Chemotherapy-Induced Amenorrhea
- Registration Number
- NCT05007834
- Lead Sponsor
- University Hospital, Lille
- Brief Summary
Chemotherapy for cancer, due to its gonadotoxicity, can lead to impaired female fertility, resulting in the occurrence of transient or prolonged chemo-induced amenorrhea (CIA). According to recent data from the National Cancer Institute, 11.9% of women under the age of 40 diagnosed with cancer have been offered a fertility evaluation within five years of diagnosis. Predicting the risk and especially the duration of the CIA remains difficult. Known factors predicting a rapid return of menstruation are a young age at diagnosis, a low gonadotoxic treatment (absence of alkylating agents) and a high pre-chemotherapy blood level of AMH reflecting a large pool of growing follicles. A body mass index (BMI) ≥ 25 kg / m² could also be a positive predictor, but this remains debated.
The objective of this project is to assess the impact of metabolism and energy reserves, physical activity and the chronotype on the recovery of ovarian function in patients with breast cancer who have developed CIA
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 50
- Women with a chemotherapy-induced (CIA) amenorrhea who asked for post-cancer fertility follow-up at the University Hospital of Lille, France.
- Women between 25 to 35 years age at inclusion
- Chemotherapy protocol: FEC 100 (3 cycles) + docetaxel (3 cycles
- Women without CIA
- Women who refuse to participate in the study
- Women older than 35 years at inclusion
- Women who received another chemotherapy protocol
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Concentration of IL-6 levels at the end of chemotherapy 1 year Study the association between the IL-6 blood levels (in pg/ml) at the end of chemotherapy and the menstrual period return state ( before or after 6 months)
- Secondary Outcome Measures
Name Time Method Correlation between blood metabolic markers (Leptin, Insulin, Ghrelin) and menstrual period return state 1 year Leptin concentration in ng/ml; insulin concentration in mUI/L; ghrelin concentrations in pg/ml
Correlation between chronotype score at the end of chemotherapy and menstrual period return state 1 year chronotype score expressed in arbitrary units
Correlation between the Physical activity Score at 3 months and the menstrual period return state (between 3 to 12 months) 9 months Physical activity score expressed in arbitrary units
Correlation between physical activity score at the end of chemotherapy and menstrual period return state 1 year Physical activity score expressed in arbitrary units
Correlation between the BMI at the end of chemotherapy and menstrual period return state 1 year weight and height will be combined to report BMI in kg/m2
Correlation between Blood metabolic markers (Leptin, Insulin, Ghrelin) assessed at 3 months and menstrual period return state 9 months Leptin concentration in ng/ml, Insulin concentration in mUI/L, Ghrelin concentration in pg/ml
Evolution of the blood concentration of insulin over the follow-up period (12 months) 1 year insulin concentrations expressed in mUI/L
Correlation between the BMI assessed at 3 months and the menstrual period return state (between 3 to 12 months) 9 months weight and height assessed at 3 months will be combined to report BMI in kg/m2
Correlation between the Chronotype Score at 3 months and the menstrual period return state (between 3 to 12 months) 9 months chronotype score expressed in arbitrary units
Evolution of the blood concentration of Leptin over the follow-up period (12 months) 1 year leptin concentrations expressed in ng/ml
Evolution of the blood concentration of Ghrelin over the follow-up period (12 months) 1 year ghrelin concentrations expressed in pg/ml
Trial Locations
- Locations (1)
Hop Jeanne de Flandre Chu Lille
🇫🇷Lille, France